Avacta (AVCT): Corp Cell therapy JV with Daewoong Pharmaceutical | Lok'nStore (LOK): Corp Second collaboration with Lidl | Shield Therapeutics (STX): Corp China licence - $62.8m bio-dollar deal | Shoe Zone (SHOE): Corp FY19 better than expected; reinvigorated focus evident
08 Jan 2020
Morning Note – 8 January 2020
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Note – 8 January 2020
- Published:
08 Jan 2020 -
Author:
Guy Hewett | Mark Brewer | Cavendish Research -
Pages:
7
Avacta (AVCT): Corp Cell therapy JV with Daewoong Pharmaceutical | Lok'nStore (LOK): Corp Second collaboration with Lidl | Shield Therapeutics (STX): Corp China licence - $62.8m bio-dollar deal | Shoe Zone (SHOE): Corp FY19 better than expected; reinvigorated focus evident